dinoprost

Small moleculeexperimental

Dinoprost is the synthetic or partially synthetic, naturally-occurring prostaglandin F2 alpha (trade mark Prostin F2 alpha). Dinoprost has been used for therapeutic termination of pregnancy. Although the exact mode of action in pregnancy termination in humans is not fully defined, when Prostin F2 alpha is administered by the intrauterine route it initiates rhythmical uterine contractions which, if continued for a sufficient time, are capable of expelling the contents of the uterus. Sensitivity of the pregnant uterus to prostaglandins is lower during early and mid-pregnancy than at term. — NCATS

Clinical trial activity

11 trials · 12 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2002 (NCT00545194)

Timeline

2000s

Jan 1, 2002
Earliest Phase 3 Sponsor(trial)

2010s

Jan 1, 2016
Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Obstetric Labor Complications

Studied for

Mechanism of action

Prostaglandin E2 receptorACTIVATOR
Prostaglandin E2 receptor activator

Chemistry & pharmacology

Loading structure…

SMILES

CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O

Mol. weight: 354.49 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Discontinued

Oral

Parenteral

Yes

Topical

Sources

Also known as

dinoprost
dinoprost
dinoprost
dinoprost
dinoprost
dinoprost
dinoprost
dinoprost
dinoprost trometamol
dinoprost trometamol
dinoprost trometamol
dinoprost trometamol
dinoprost tromethamine
dinoprost tromethamine
enzaprost
pge2
pge2
pgf2-alpha tham
pgf2-alpha tham
pgf2alpha tham
pgf2alpha tham
pgf2alpha-tham
pgf2alpha-tham
prepidil
prepidil
prepidil
prostaglandin e2
prostaglandin e2
prostaglandin e2
prostaglandin f2
prostaglandin f 2 alpha
prostaglandin f2 alpha
prostaglandin f2 alpha
prostaglandin f2-alpha tham
prostaglandin f2-alpha tham
prostaglandin f2alpha tham
prostaglandin f2alpha tham
prostaglandin f2a tromethamine
prostaglandin f2a tromethamine
prostin f2 alpha
prostin f2 alpha
u-14583
u-14583
u-14583e
u-14583e

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02801227	Phase 4	Sep 1, 2016	Hebrew University
NCT02861079	Phase 2	Aug 1, 2016	Zeynep Kamil Maternity and Childen Education and Training Hospital
NCT02856724	Phase 2	Aug 1, 2016	Zeynep Kamil Maternity and Childen Education and Training Hospital
NCT00815542	Phase 3	Jun 1, 2012	Tel Aviv University
NCT01327118	N/A	Sep 1, 2010	University of Copenhagen
NCT01390233	N/A	Jul 1, 2010	University of South Carolina
NCT01689311	N/A	Mar 1, 2009	Canadian Anesthesiologists' Society, Icahn School of Medicine at Mount Sinai, University of Toronto
NCT00355303	Phase 4	Aug 1, 2006	Nilratan Sircar Medical College
NCT00374530	N/A	Aug 1, 2006	University of Copenhagen
NCT00355966	Phase 4	Aug 1, 2006	Nilratan Sircar Medical College, Nil Ratan Sircar Medical College and Hospital
NCT00545194	Phase 3	Jan 1, 2002	Institut National de la Santé Et de la Recherche Médicale, France, University of Turku

Showing 11 of 11 trials

Page 1 / 1

Organizations

Research & Development (12)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Nilratan Sircar Medical College	Academic/Hospital	2	2	1	2006
University of Copenhagen	Academic/Hospital	2	2	1	2006
Zeynep Kamil Maternity and Childen Education and Training Hospital	Academic/Hospital	2	2	1	2016
Canadian Anesthesiologists' Society	Academic/Hospital	1	0	1	2009
Hebrew University	Academic/Hospital	1	1	1	2016
Icahn School of Medicine at Mount Sinai	Academic/Hospital	1	1	1	2009
Institut National de la Santé Et de la Recherche Médicale, France	Academic/Hospital	1	1	1	2002
Nil Ratan Sircar Medical College and Hospital	Academic/Hospital	1	0	1	2006
Tel Aviv University	Academic/Hospital	1	1	1	2012
University of South Carolina	Academic/Hospital	1	1	1	2010
University of Toronto	Academic/Hospital	1	0	1	2009
University of Turku	Academic/Hospital	1	0	1	2002

12 organizations

Page 1 / 1